Influenza pandemic

Global Influenza Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Infectious diseases, Pharmaceutical, Health, Influenza, Medical specialties, Health care, Health, Influenza vaccine, Influenza pandemic

b'The "Global Influenza Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Influenza Epidemiology and Patient Flow Analysis - 2021, provides Influenza epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Influenza Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Influenza Epidemiology and Patient Flow Analysis - 2021, provides Influenza epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Influenza patients, history of the disease at the population level (Influenza prevalence, Influenza incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Influenza patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Influenza market sizing, assessing market potential, and developing drug forecast models\nIdentify Influenza patients segments through age groups, gender, and disease sub-types\n'

Global Avian Influenza Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 30, 2021
Infectious diseases, Health, Clinical trials, Health sciences, Health, Clinical research, Pharmaceutical industry, Drug discovery, Agricultural health and safety, Animal virology, Avian influenza, Clinical trial, Influenza, Influenza pandemic, Influenza research

The "Global Avian Influenza Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Avian Influenza Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Avian Influenza Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Avian Influenza market.
  • It covers emerging therapies for Avian Influenza in active clinical development stages including early and late stage clinical trials.
  • The report provides Avian Influenza pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older

Retrieved on: 
Wednesday, February 3, 2021
Chemical compounds, Influenza, Organic compounds, Infectious diseases, Baloxavir marboxil, Influenza pandemic

Prior to this approval, RAPIVAB had been indicated for patients two years and older.

Key Points: 
  • Prior to this approval, RAPIVAB had been indicated for patients two years and older.
  • Influenza can have serious and deadly consequences and we are very pleased that the FDA has extended the approved indication for RAPIVAB to include patients as young as six months.
  • RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
  • Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB.

New Jersey's Millers Pharmacy Offers The Yale PCR SalivaDirect™ COVID-19 Test

Retrieved on: 
Tuesday, December 15, 2020
Health sciences, Health, Coronavirus disease, Occupational safety and health, Zoonoses, Pharmacy, Compounding, Severe acute respiratory syndrome, Influenza pandemic, Animal diseases

The Yale SalivaDirect is a qualitative test for the detection of nucleic acid from SARS-CoV-2 in saliva collected without preservatives in a sterile container from individuals suspected of COVID-19.It requires just saliva.

Key Points: 
  • The Yale SalivaDirect is a qualitative test for the detection of nucleic acid from SARS-CoV-2 in saliva collected without preservatives in a sterile container from individuals suspected of COVID-19.It requires just saliva.
  • Results are delivered typically the next day, within 12-48 hours from the time that the test reaches the lab.
  • Millers is a Homecare and Compounding pharmacy, dispensing wellness since 1919, opening in the midst of the 1918 Spanish Flu pandemic.
  • Millers Pharmacy of Wyckoff offers regular and Compounding medication, surgical supplies, home medical equipment, etc.

Avian influenza: virus spreading rapidly in Europe

Retrieved on: 
Friday, November 20, 2020
Animal virology, Veterinary medicine, Health sciences, Health, Influenza A virus subtype H5N1, Agricultural health and safety, Avian influenza, Influenza, Influenza pandemic

The risk of avian influenza moving into previously unaffected European countries is high, according to an update published today by EFSA which shows that the virus is spreading rapidly across the continent.

Key Points: 
  • The risk of avian influenza moving into previously unaffected European countries is high, according to an update published today by EFSA which shows that the virus is spreading rapidly across the continent.
  • The majority of the detections were in wild birds although there have been a handful of outbreaks in poultry.
  • The new report rates the likelihood of the virus spreading from wild birds to poultry as high.
  • The report was produced with the support of the European Centre for Disease Prevention and Control (ECDC) and the European Reference Laboratory for Avian Influenza.

Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020

Retrieved on: 
Wednesday, October 21, 2020
Articles, Health, Medical specialties, RTT, Epidemiology, Zoonoses, Influenza pandemic, Prevention, Influenza, Orthomyxoviridae, Virus, Influenza research

In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish influenza pandemic.

Key Points: 
  • In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish influenza pandemic.
  • VIR-2482 has been half-life engineered so that a single dose has the potential to last the entire influenza season, which is typically five to six months long.
  • Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
  • Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.

Avian influenza: EU on alert for new outbreaks

Retrieved on: 
Thursday, October 1, 2020
Health, Articles, Veterinary medicine, Avian influenza, Influenza, Influenza A virus subtype H5N1, Influenza pandemic

EU countries are being urged to step up surveillance and biosecurity measures to guard against possible new outbreaks of avian influenza this year.

Key Points: 
  • EU countries are being urged to step up surveillance and biosecurity measures to guard against possible new outbreaks of avian influenza this year.
  • The warning follows outbreaks of highly pathogenic avian influenza (HPAI) among wild and domestic birds in western Russia and Kazakhstan over the past few months.
  • Northern and eastern Europe are likely to be the most vulnerable to new outbreaks given past experience.
  • The alert is included in the latest update on avian influenza in Europe and beyond.

Celdara Medical Announces Receipt of NIH Funding for Pandemic Influenza Antiviral Development

Retrieved on: 
Wednesday, August 12, 2020
Articles, Influenza A virus subtype H1N1, Public Health Emergency of International Concern, Swine flu pandemic, Pandemic, Influenza A virus subtype H3N2, Influenza A virus subtype H2N2, Influenza pandemic

"We are extremely grateful for this support, especially during these challenging times," said Dr. Jake Reder, co-founder and CEO of Celdara.

Key Points: 
  • "We are extremely grateful for this support, especially during these challenging times," said Dr. Jake Reder, co-founder and CEO of Celdara.
  • The H1N1 pandemic of 1918 claimed at least 50 million lives worldwide, while the H2N2 pandemic of 1957 and the H3N2 pandemic of 1968 each claimed over a million lives globally.
  • Celdara Medical initiated this work in 2014 and formalized it under the Pandemic Security Initiative umbrella in early 2020 to capture learnings from, and aid in the response to, COVID-19.
  • Celdara Medical gives hope and health to patients by transforming academic innovations into medicines with the potential to cure the world's most challenging diseases.

Committee asks top advisors about scientific evidence used in COVID-19 pandemic

Retrieved on: 
Wednesday, July 15, 2020
Articles, Viruses, Health, Global health, Pandemic, Vaccine, Influenza pandemic

In what ways has evidence been interpreted differently in England compared to other UK nations and other countries during the pandemic?

Key Points: 
  • In what ways has evidence been interpreted differently in England compared to other UK nations and other countries during the pandemic?
  • What is the goal of the strategy in England until there is a vaccine or highly effective treatment?
  • To what extent is the scientific evidence pointing towards a "second wave" of the virus?
  • What lessons have been learnt about the importance of transparency in ensuring the public have trust in the scientific advice given to Government?